Omnix Medical, a biotech company dedicated to the development of novel antimicrobial pharmaceuticals against drug-resistant bacteria, today announced the appointment of Antonius (Toni) Schuh, Ph.D., to its Board of Directors. Dr. Schuh is a Managing Partner of Global Source Ventures. He has over 20 years of executive leadership experience in the biotechnology, healthcare and life sciences industries and has served as CEO of five life sciences companies, including Arcturus Bioscience, AviaraDx (now bioTheranostics), Sequenom (NASDAQ: SQNM), Sorrento Therapeutics (NASDAQ: SRNE) and Trovagene (NASDAQ: TROV). In each case, he developed the company’s strategy based on a focused value proposition, oversaw the execution of such strategy, and secured funding to achieve transforming milestones, including multiple product launches. He delivered significant returns for investors at exit (public offering or acquisition). Toni is a certified pharmacist and earned his Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany.

Moshik Cohen-Kutner, CEO of Omnix Medical, said, “We are delighted to welcome Toni to the Board. Toni is highly-respected in the biotechnology, healthcare and life sciences industries. He supports Omnix Medical’s determination to address the global threat of drug-resistant infections by developing an arsenal of novel, safe, effective, and fast-acting antibiotic agents targeting multidrug-resistant (MDR) bacteria. Toni’s leadership experience will add a valuable perspective to our Board as the Company moves into this next phase of clinical development with our lead peptide OMN6.”

Dr. Schuh commented, “I look forward to working closely with the board and management team to advance the Company’s objectives as it moves OMN6, the Company’s lead compound designed to treat A. baumannii infections – a major threat for hospitalized patients – from preclinical to clinical development and commercialization.”


Omnix Medical is a biotechnology company founded in 2015. Headquartered in Jerusalem, Israel, the company employs eight scientists advancing in-house research and development as well as closely directing studies with top-tier international contract research organizations.

Omnix’s technology is inspired by the innate immune system of insects, employing a strategy that has been proven very efficient for 250 million years. Insects combat pathogenic bacteria using a unique family of Antimicrobial Peptides that physically damage bacterial membranes with no toxic effects. The rapid bactericidal Mechanism of Action employed by these peptides is active against Gram(-) multidrug-resistant pathogens, the ESKAPE bacteria: K. pneumonia spp, A. baumannii, P. aeruginosa and Enterobacter spp. These bacteria are the most serious and urgent threats to public health leading to ~50% mortality among infected patients in Intensive Care Units.

Investor Contact

Moshik Cohen-Kutner, CEO

Rom Lakritz, CFO/COO
+1 646 9346699

Media Contact

Niv Bachnoff, CSO
+ 972-54-238-6023

Related Links



More To Explore